Effect of Spironolactone on COVID-19 in Patients With Underlying Liver Cirrhosis: A Nationwide Case-Control Study in South Korea
et al., Frontiers in Medicine,
Retrospective 6,462 liver cirrhosis patients in South Korea, with 67 COVID+ cases, showing significantly lower COVID-19 cases with spironolactone treatment. Death and ICU results per group are not provided. Complications in this study included receipt of antivirals, e.g., treatment with oseltamivir.
risk of case, 77.0% lower, OR 0.23, p = 0.005, treatment 6 of 49 (12.2%) cases,
89 of 245 (36.3%) controls, NNT 6.5, case control OR, model 2, within 3 months.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Jeon et al., 2/23/2021, retrospective, South Korea, Asia, peer-reviewed, 3 authors.